<?xml version='1.0' encoding='UTF-8'?><?xml-stylesheet href='static/style.xsl' type='text/xsl'?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-22T11:00:00Z</responseDate><request verb="GetRecord" identifier="oai:ecommons.cornell.edu:1813/115772" metadataPrefix="dim">https://ecommons.cornell.edu/server/oai/request</request><GetRecord><record><header><identifier>oai:ecommons.cornell.edu:1813/115772</identifier><datestamp>2026-05-15T19:43:51Z</datestamp><setSpec>com_1813_35</setSpec><setSpec>col_1813_47</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="author">Zhao, WeiYang</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="chair" lang="en_US">Liu, Rui</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Glahn, Raymond</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="committeeMember" lang="en_US">Liaukonyte, Jurate</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2024-10-16T20:20:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2024-10-16T20:20:00Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2023-12</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Submission ID: 14026</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="other">ProQuest Publication ID: 30688045</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://hdl.handle.net/1813/115772</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="doi">http://doi.org/10.7298/s8zc-g044</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="bibid">16454796</dim:field>
   <dim:field mdschema="dc" element="description" lang="en_US">149 pages</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">Breast cancer, notably Triple-negative breast cancer (TNBC), a subtype lacking expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor II (HER2), remains a significant global health issue due to its poor prognosis and high invasiveness. This study investigates oleanolic acid (OA), a compound that exhibits a broad spectrum of biological activities, such as anti-inflammatory, hepatoprotective, analgesic, cardiotonic, sedative, and anticancer properties. Numerous investigations have explored the potential health advantages of OA derived from natural sources, identifying it as a promising candidate for the development of novel preventative and therapeutic agents for various ailments. Additionally, the abundance of OA in plant-based foods renders it an appealing target for dietary interventions and the development of functional foods. However, the anti-cancer profile of OA against TNBC cells has not been fully elucidated. We discovered that OA could inhibit TNBC MDA-MB-231 cell proliferation and induce cell cycle arrest. OA's effect is realized through the downregulation of cyclin D1, CDK4, and p-cdc25c activities, analyzed via methylene blue assay, flow cytometry, and Western Blot. Moreover, OA was found to disrupt EGFR/Ras/ PI3K/ AKT/mTOR and EGFR/ERK1/2/GSK-3β pathways, thereby modulating cell cycle checkpoint proteins p53 and p21Cip1/Waf1. We also noted OA's ability to counteract EGF-induced protein upregulation and to promote cell cycle checkpoint proteins. Our study further elucidates the pro-apoptotic role of OA. The compound's apoptotic influence, marked by increased BAD and cytochrome c expression, was observed under various dosages. OA also induced a decrease in ATP production, signifying a metabolic shift, and downregulated mitochondrial-associated BCL-2 family proteins, potentially affecting apoptosis initiation markers. OA additionally modulated key apoptotic and cell cycle regulators in an EGF-stimulated cell model, leading to upregulated expressions of p21Cip1/Waf1, p53, caspase-9 and caspase-3, and a decrease in p-JNK expression. Lastly, our investigation into OA's anti-metastatic properties reveals its ability to downregulate matrix metalloproteinases MMP-2 and MMP-9, decrease the activity of released MMP-2 by modified zymography, and the reduced expression of migration marker VEGF, regulated by the c-Jun transcription factor. These findings suggest that OA's inhibitory effect on metastasis occurs via EGFR/p38 MAPK/JAK3/STAT-3, EGFR/ERK/STAT-3, and EGFR/JNK/c-Jun signaling pathways. Results of this study illuminate OA's potential therapeutic benefits in managing TNBC proliferation, apoptosis, and metastasis, thereby offering a promising avenue for the development of more effective treatment strategies from the perspective of diet and cancer.</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Diet and Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Oleanolic Acid</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Phytochemicals</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Triple-Negative Breast Cancer</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">ANTI-CANCER ACTIVITIES OF OLEANOLIC ACID AGAINST  TRIPLE-NEGATIVE BREAST CANCER CELLS: MECHANISMS OF ACTION</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">dissertation or thesis</dim:field>
   <dim:field mdschema="dc" element="relation" qualifier="localuri">https://newcatalog.library.cornell.edu/catalog/16454796</dim:field>
   <dim:field mdschema="dc" element="format" qualifier="mimetype">application/pdf</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="discipline">Food Science and Technology</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="grantor">Cornell University</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="level">Doctor of Philosophy</dim:field>
   <dim:field mdschema="thesis" element="degree" qualifier="name">Ph. D., Food Science and Technology</dim:field>
   <dim:field mdschema="dcterms" element="license">https://hdl.handle.net/1813/59810.2</dim:field>
   <dim:field mdschema="dspace" element="entity" qualifier="type">Publication</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="collection" authority="https://cornell-ecommons.eks.prod.4science.cloud/handle/1813/47" confidence="600">Cornell Theses and Dissertations</dim:field>
   <dim:field mdschema="cris" element="virtual" qualifier="author">Zhao, WeiYang</dim:field>
   <dim:field mdschema="cris" element="virtualsource" qualifier="collection">5893a6ea-7af3-41d7-abc6-04bcd26ab5df</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
   <dim:field mdschema="cerif" element="openaire" authority="" confidence="-1">&lt;Publication xmlns="https://www.openaire.eu/cerif-profile/1.1/" id="3d4235ba-1190-475d-adb5-a263a4a7ef50">
	&lt;Type xmlns="https://www.openaire.eu/cerif-profile/vocab/COAR_Publication_Types">http://purl.org/coar/resource_type/c_1843&lt;/Type>
	&lt;Language>en&lt;/Language>
   	&lt;Title>ANTI-CANCER ACTIVITIES OF OLEANOLIC ACID AGAINST  TRIPLE-NEGATIVE BREAST CANCER CELLS: MECHANISMS OF ACTION&lt;/Title>
   	&lt;PublishedIn>
    	&lt;Publication>
      	&lt;/Publication>
   	&lt;/PublishedIn>
   	&lt;PublicationDate>2023-12&lt;/PublicationDate>
   	&lt;DOI>http://doi.org/10.7298/s8zc-g044&lt;/DOI>
   	&lt;Authors>
      	&lt;Author>
        	&lt;DisplayName>Zhao, WeiYang&lt;/DisplayName>
         	&lt;Affiliation>
         		&lt;OrgUnit>
         		&lt;/OrgUnit>
         	&lt;/Affiliation>
      	&lt;/Author>
	&lt;/Authors>
   	&lt;Editors>
	&lt;/Editors>
    &lt;Publishers>
        &lt;Publisher>
            &lt;OrgUnit />
        &lt;/Publisher>
    &lt;/Publishers>
    &lt;Keyword>Diet and Cancer&lt;/Keyword>
    &lt;Keyword>Oleanolic Acid&lt;/Keyword>
    &lt;Keyword>Phytochemicals&lt;/Keyword>
    &lt;Keyword>Triple-Negative Breast Cancer&lt;/Keyword>
   	&lt;Abstract>Breast cancer, notably Triple-negative breast cancer (TNBC), a subtype lacking expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor II (HER2), remains a significant global health issue due to its poor prognosis and high invasiveness. This study investigates oleanolic acid (OA), a compound that exhibits a broad spectrum of biological activities, such as anti-inflammatory, hepatoprotective, analgesic, cardiotonic, sedative, and anticancer properties. Numerous investigations have explored the potential health advantages of OA derived from natural sources, identifying it as a promising candidate for the development of novel preventative and therapeutic agents for various ailments. Additionally, the abundance of OA in plant-based foods renders it an appealing target for dietary interventions and the development of functional foods. However, the anti-cancer profile of OA against TNBC cells has not been fully elucidated. We discovered that OA could inhibit TNBC MDA-MB-231 cell proliferation and induce cell cycle arrest. OA&amp;apos;s effect is realized through the downregulation of cyclin D1, CDK4, and p-cdc25c activities, analyzed via methylene blue assay, flow cytometry, and Western Blot. Moreover, OA was found to disrupt EGFR/Ras/ PI3K/ AKT/mTOR and EGFR/ERK1/2/GSK-3β pathways, thereby modulating cell cycle checkpoint proteins p53 and p21Cip1/Waf1. We also noted OA&amp;apos;s ability to counteract EGF-induced protein upregulation and to promote cell cycle checkpoint proteins. Our study further elucidates the pro-apoptotic role of OA. The compound&amp;apos;s apoptotic influence, marked by increased BAD and cytochrome c expression, was observed under various dosages. OA also induced a decrease in ATP production, signifying a metabolic shift, and downregulated mitochondrial-associated BCL-2 family proteins, potentially affecting apoptosis initiation markers. OA additionally modulated key apoptotic and cell cycle regulators in an EGF-stimulated cell model, leading to upregulated expressions of p21Cip1/Waf1, p53, caspase-9 and caspase-3, and a decrease in p-JNK expression. Lastly, our investigation into OA&amp;apos;s anti-metastatic properties reveals its ability to downregulate matrix metalloproteinases MMP-2 and MMP-9, decrease the activity of released MMP-2 by modified zymography, and the reduced expression of migration marker VEGF, regulated by the c-Jun transcription factor. These findings suggest that OA&amp;apos;s inhibitory effect on metastasis occurs via EGFR/p38 MAPK/JAK3/STAT-3, EGFR/ERK/STAT-3, and EGFR/JNK/c-Jun signaling pathways. Results of this study illuminate OA&amp;apos;s potential therapeutic benefits in managing TNBC proliferation, apoptosis, and metastasis, thereby offering a promising avenue for the development of more effective treatment strategies from the perspective of diet and cancer.&lt;/Abstract>
	&lt;Access xmlns="http://purl.org/coar/access_right" 
    >
    &lt;/Access>
&lt;/Publication>
</dim:field>
</dim:dim>
</metadata></record></GetRecord></OAI-PMH>